Sumiko Okubo

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Journal: International journal of clinical oncology
Published: September 13, 2023

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

Journal: International journal of hematology
Published: March 24, 2023

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.

Journal: Japanese journal of clinical oncology
Published: November 17, 2022

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

Journal: Japanese journal of clinical oncology
Published: August 11, 2021

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.

Journal: Japanese journal of clinical oncology
Published: May 13, 2021

Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.

Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.

Journal: Japanese journal of clinical oncology
Published: December 17, 2020

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.

Journal: Cancer medicine
Published: October 29, 2020

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Journal: International journal of hematology
Published: May 07, 2020

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 19, 2019

Development and application of 2.5 GPa-25 T high-pressure high-field electron spin resonance system using a cryogen-free superconducting magnet.

Development and application of 2.5 GPa-25 T high-pressure high-field electron spin resonance system using a cryogen-free superconducting magnet.

Journal: Journal of magnetic resonance (San Diego, Calif. : 1997)
Published: June 19, 2018

Fast x-ray detector system with simultaneous measurement of timing and energy for a single photon.

Fast x-ray detector system with simultaneous measurement of timing and energy for a single photon.

Journal: The Review of scientific instruments
Published: July 03, 2017

High-field/high-pressure ESR.

High-field/high-pressure ESR.

Journal: Journal of magnetic resonance (San Diego, Calif. : 1997)
Published: December 08, 2016
Showing 1-12 of 18

Last Updated: 09/26/2026